title: [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers].
abstract: New blood vessel formation (angiogenesis) is fundamental to the process of tumor. Vascular Endothelial Growth Factors (VEGF) and their receptors are considered to be ones of the most important regulators of angiogenesis and new key targets for anti-cancer treatment. Three angiogenesis inhibitors are approved in France for patients with various malignancies. The main purpose of this review is to summarize the basic mechanisms of tumor angiogenesis and the reasons why angiogenesis inhibitors arouse therapeutic interest. However, for these drugs, fundamental pharmacodynamic effects observed in laboratory studies were not always translated to efficacy in clinical development. Moreover, many side effects were reported and may discourage from using it. Their optimal use should be necessary to minimize side effects and guarantee therapeutic progress.
authors.affiliation: Laboratoire de pharmacodynamie, UMR INSERM 608, Faculté de Pharmacie, Marseille, France. youssef.bennis@ap-hm.fr
authors.forename: Youssef
authors.initials: Y
authors.lastname: Bennis
authors.forename: Benjamin
authors.initials: B
authors.lastname: Guillet
authors.forename: Christophe
authors.initials: C
authors.lastname: Curti
authors.forename: Pascale
authors.initials: P
authors.lastname: Pisano
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D000068258:Bevacizumab; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D000077210:Sunitinib